Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK

References

• GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.
   PubMed Web of Science ®Google Scholar
• Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology. 2000;47(31):49–56.
   Google Scholar
• Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12(2):123–130.
   PubMed Web of Science ®Google Scholar
• Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol. 2013;26(2):104–113.
   PubMedGoogle Scholar
• Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther. 2006;24(11–12):1507‐1523.
   Web of Science ®Google Scholar
• Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine. 2015;94:e963.
   PubMed Web of Science ®Google Scholar
• Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol. 2014;20:3542–3551.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15(37):4659–4665.
   Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. J Crohns Colitis. 2015;9(3):211–222.
   Google Scholar
• Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6(3):62–72.
   PubMedGoogle Scholar
• Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017;66(5):863–871.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Ferinject (ferric carboxymaltose). Available from: https://www.medicines.org.uk/emc/product/5910/smpc. Accessed March 13, 2020.
   Google Scholar
• Electronic Medicines Compendium. Monofer 100mg/mL solution for injection/infusion. Available from https://www.medicines.org.uk/emc/product/5676. Accessed March 13, 2020.
   Google Scholar
• Electronic Medicines Compendium. Venofer (iron sucrose) 20 mg iron/mL, solution for injection or concentrate for solution for infusion. https://www.medicines.org.uk/emc/product/5911. Accessed March 13, 2020.
   Google Scholar
• Evstatiev R, Marteau P, Iqbal T, et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–853.e1-2.
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–1192.
   PubMed Web of Science ®Google Scholar
• Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838–845.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108(12):1877–1888.
   PubMed Web of Science ®Google Scholar
• Schröder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100(11):2503–2509.
   PubMed Web of Science ®Google Scholar
• Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1303–1318.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Developing NICE guidelines: the manual: 7 Incorporating economic evaluation Available from: https://www.nice.org.uk/process/pmg20/chapter/incorporating-economic-evaluation. Accessed March 13, 2021.
   Google Scholar
• Khunti K, Gillies CL, Taub NA, et al. A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: modelling study. Diabetes Res Clin Pract. 2012;97(3):505–513.
   Web of Science ®Google Scholar
• Katz P, Showstack J, Smith JF, et al. Costs of infertility treatment: results from an 18-month prospective cohort study. Fertil Steril. 2011;95(3):915–921.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017;14(12):1439–1446.
   PubMed Web of Science ®Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397–401.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al.; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Available from: www.nice.org.uk/bnf. Accessed March 13, 2020.
   Google Scholar
• Curtis L, Burns A. Unit Costs of Health and Social Care 2019, Personal Social Services Research Unit. Canterbury: University of Kent; 2018. doi:10.22024/UniKent/01.02.79286
   Google Scholar
• National Institute for Health and Care Excellence. Implementing the NICE guideline on anaemia management in people with chronic kidney disease (NG8). Available from: https://www.nice.org.uk/guidance/ng8/resources/costing-statement-pdf-72504685. Accessed March 13, 2020.
   Google Scholar
• Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397–406.
   PubMed Web of Science ®Google Scholar
• Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432–443.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Goodhand JR, Rampton DS. Editorial: which iron preparation for patients with IBD? Aliment Pharmacol Ther. 2017;46(2):194–195.
   Web of Science ®Google Scholar
• Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Editorial: which iron preparation for patients with IBD? Authors’ reply. Aliment Pharmacol Ther. 2017;46(2):195–196.
   Web of Science ®Google Scholar
• Reinisch W, Lindgren S. Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies. Aliment Pharmacol Ther. 2017;46(7):704–705.
   PubMed Web of Science ®Google Scholar
• Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies-authors’ reply. Aliment Pharmacol Ther. 2017;46(7):705–706.
   Web of Science ®Google Scholar
• Aksan A, Işık H, Aksan S, Tuğal D, Dignass A, Stein JM. P585 Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: preliminary results from the IBD subgroup analysis. J Crohn’s Colitis. 2020;14(Supplement_1):S490–S490.
   Google Scholar
• Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104(6):1460–1467.
   PubMed Web of Science ®Google Scholar
• Riemsma R, Al M, Ramos I, et al. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(61).
   Web of Science ®Google Scholar
• Baguet T, Verhoeven J, De Vos F, Goethals I. Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma. Front Oncol. 2019;9:814.
   PubMed Web of Science ®Google Scholar
• Wehler E, Boytsov N, Nicolay C, Herrera-Restrepo O, Kowal S. A budget impact and cost per additional responder analysis for baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to tumor necrosis factor inhibitors in the USA. Pharmacoeconomics. 2020;38(1):39–56.
   Web of Science ®Google Scholar
• Strand V, Elaine Husni M, Betts KA, et al. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatol. 2018;2:3.
   PubMedGoogle Scholar
• Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. Int J Chron Obstruct Pulmon Dis. 2018;13:3867–3877.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Acad Dermatol. 2016;75(4):740–746.
   PubMed Web of Science ®Google Scholar